{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:21Z","timestamp":1790217381980,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ophtha.2014.05.015","type":"journal-article","created":{"date-parts":[[2014,7,4]],"date-time":"2014-07-04T10:30:27Z","timestamp":1404469827000},"page":"2212-2219","source":"Crossref","is-referenced-by-count":172,"title":["Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"2009-012609-20","registry":"10.18810\/euctr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2104-9239","authenticated-orcid":false,"given":"Domenico","family":"Lepore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham E.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Molle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Baldascino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sammartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velia","family":"Purcaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Giannantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Papacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-2943","authenticated-orcid":false,"given":"Costantino","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.05.015_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1084-2756(03)00119-2","article-title":"Pathogenesis of retinopathy of prematurity","volume":"8","author":"Smith","year":"2003","journal-title":"Semin Neonatol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ophtha.2010.04.021","article-title":"Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity","volume":"118","author":"Lepore","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.05.015_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy: preliminary results","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib4","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ajo.2010.10.007","article-title":"Outcomes of a protocol-based management for zone 1 retinopathy of prematurity: the Indian Twin Cities ROP Screening Program report number 2","volume":"151","author":"Jalali","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/IAE.0b013e3181a68f3a","article-title":"Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment","volume":"29","author":"Sanghi","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.05.015_bib7","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","article-title":"Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia","volume":"15","author":"Stone","year":"1995","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.ophtha.2014.05.015_bib8","first-page":"1217","article-title":"Vascularization of the human fetal retina: role of vasculogenesis and angiogenesis","volume":"41","author":"Hughes","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.05.015_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/edrv-13-1-18","article-title":"Molecular and biological properties of the vascular endothelial growth factor family of proteins","volume":"13","author":"Ferrara","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ophtha.2014.05.015_bib10","first-page":"1992","article-title":"Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy","volume":"7","author":"Harris","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ophtha.2014.05.015_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of vascular endothelial growth factors prevents retinal ischemia-associated iris neovascularization in a nonhuman primate","volume":"114","author":"Adamis","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib12","first-page":"290","article-title":"Role of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity","volume":"37","author":"Stone","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.05.015_bib13","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ophtha.2014.05.015_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","article-title":"Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration","volume":"22","year":"2002","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.05.015_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.ophtha.2014.05.015_bib16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.05.015_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity","volume":"55","author":"Shah","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2014.05.015_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"issue":"Suppl","key":"10.1016\/j.ophtha.2014.05.015_bib20","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.05.015_bib21","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","article-title":"Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity","volume":"245","author":"Chung","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib22","first-page":"6","article-title":"Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"14","author":"Law","year":"2010","journal-title":"J\u00a0AAPOS"},{"issue":"Suppl","key":"10.1016\/j.ophtha.2014.05.015_bib23","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":"Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.05.015_bib24","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08820530701543024","article-title":"Intravitreal ranibizumab and bevacizumab: a review of risk","volume":"22","author":"Dafer","year":"2007","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib26","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.ophtha.2014.05.015_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice","volume":"118","author":"Moshfeghi","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.05.015_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib29","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.05.015_bib31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2014.05.015_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014004357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014004357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T20:37:13Z","timestamp":1598042233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642014004357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0161642014004357"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.015","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}